secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2026-06-01T20:05:16+00:00
Accession:  0001193125-26-251394
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review
--------------------------------------------------------------------------------

- Discontinued pociredir for sickle cell disease after FDA feedback; no viable regulatory path forward.
- FDA cited secondary malignancy risk from another PRC2 inhibitor (Tazverik) withdrawn March 2026.
- Company will explore strategic alternatives (merger, acquisition, etc.) and reduce operating expenses.
- Held $333.3M in cash, cash equivalents, and marketable securities as of March 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/0001193125-26-251394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-251394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer